Memantine Hydrochloride
Product Images NDC 71335-1798

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Celltrion Logo)

FDA Label Image

Label (Lbl713351798)

This is a description of a medication package for Namenda 5mg Tablet, manufactured by Vivimed Life Sciences Pvt Ltd. The package has been prepacked by Bryant Ranck and includes 30 tablets, with expiration date MM/YY. The NDC number is 7133517981. The package has instructions to store at room temperature and a warning to keep out of reach of children. The last line appears to be a barcode or product identification number.*

FDA Label Image

Structure (Memantinehcltab Figure 01)

FDA Label Image

Figure1 (Memantinehcltab Figure 02)

The text is a table showing the mean change from baseline in ADCS-ADL Score after 12 weeks of treatment with either placebo or Memantine HCI. It also mentions "Clinical Improvement."*

FDA Label Image

Figure2 (Memantinehcltab Figure 03)

This is a plot showing the cumulative percentage of patients for two different treatments, Placebo and MEMANTINE HCI, with respect to the ADCS-ADL Change from Baseline. The plot indicates that more patients on MEMANTINE HCI experienced a decrease in ADCS-ADL score compared to Placebo.*

FDA Label Image

Figure3 (Memantinehcltab Figure 04)

FDA Label Image

Figure4 (Memantinehcltab Figure 05)

The text is describing a graph that shows the cumulative percentage of patients who were given either Placebo or Memantine HCI and the change from baseline in terms of SIB (Severe Impairment Battery) scores. The graph has a scale from -10 to 10, with the increments of 5. However, there is no clear indication of what the graph is intended to show or what it is meant to be used for.*

FDA Label Image

Figure5 (Memantinehcltab Figure 06)

FDA Label Image

Figure6 (Memantinehcltab Figure 07)

The provided text seems to be a graphical representation of the "Cumulative Percentage of Patients" over time, illustrated through a chart. It showcases the effect of two treatments "Placebo/Donepezil" and "MEMANTINE HCI/Donepezil" on "ADCS-ADL Change from Baseline" scale. However, without the actual chart, it is not possible to provide more information.*

FDA Label Image

Figure7 (Memantinehcltab Figure 08)

FDA Label Image

Figure8 (Memantinehcltab Figure 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.